Non-Vitamin K Oral Anticoagulants May Be Best for Early-Stage CKD

TUESDAY, July 16, 2019 -- Non-vitamin K oral anticoagulants (NOACs) have a superior benefit-risk profile to that of vitamin K antagonists (VKAs) for patients with early-stage chronic kidney disease (CKD), according to a review published online July...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news

Related Links:

Conclusion: For the treatment of anemia in Chinese patients with CKD ND, roxadustat is much more effective than a placebo; moreover, it is cost-effective at conventional WTP thresholds. PMID: 32249625 [PubMed - as supplied by publisher]
Source: Expert Review of Pharmacoeconomics and Outcomes Research - Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research
Condition:   Chronic Kidney Diseases Interventions:   Dietary Supplement: Melatonin;   Dietary Supplement: Placebo Sponsor:   University of Oklahoma Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Contrast-induced kidney damage can occur after angiography in patients with chronic kidney disease, but the actual risk appears low and new data suggest it may be prevented by a novel drug.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news
ConclusionsThe risk of a subsequent major non-hip fragility fractures following hip fracture was not increased in patients with CKD G3 –G5 compared to eGFR>  60 ml/min. Mortality risk was higher in both hip fracture and non-hip fracture patients with CKD G4 and G5. The higher mortality risk may, as competing risk, explain our main finding of no increased or even decreased subsequent fracture risk after a hip fracture in patients with CKD G3–G5.
Source: Osteoporosis International - Category: Orthopaedics Source Type: research
Semin Thromb Hemost DOI: 10.1055/s-0040-1708841Rates of thrombosis and bleeding episodes are both increased in patients with advanced chronic kidney disease (CKD). The pathogenic mechanisms of thrombosis in these patients include platelet activation, increased formation of platelet-leukocyte conjugates, and platelet-derived microparticles, as well as effects of uremic toxins on platelets. On the other side of the coin, platelet hyporeactivity mediated by uremic toxins and anemia contributes to the increased bleeding risk in advanced CKD. Platelets also contribute to the inflammatory environment, thus increasing the risk of...
Source: Seminars in Thrombosis and Hemostasis - Category: Hematology Authors: Tags: Review Article Source Type: research
Conditions:   Sickle Cell Disease;   Sickle Cell Nephropathy Intervention:   Drug: Voxelotor Sponsors:   University of Illinois at Chicago;   Global Blood Therapeutics Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Vascular calcification progression has been associated with the loss of trabecular bone in chronic kidney disease (CKD) patients. There are few data evaluating the relationship between cortical bone loss and v...
Source: BMC Nephrology - Category: Urology & Nephrology Authors: Tags: Research article Source Type: research
AbstractDaprodustat is a prolyl hydroxylase inhibitor that stimulates erythropoiesis in a manner similar to the natural response to hypoxia, whereby inhibition of hypoxia inducible factor (HIF) prolyl ‐4‐hydroxylases by daprodustat ultimately results in increased levels of HIF‐responsive genes. Daprodustat is under development as an emerging new class of agents for the treatment of anemia associated with chronic kidney disease (CKD). This was a single‐center, single‐dose, open‐label, randomized, 2‐way crossover study in healthy Japanese male participants consisting of 2 parts. The primary objective was to eva...
Source: Clinical Pharmacology in Drug Development - Category: Drugs & Pharmacology Authors: Tags: Original Manuscript Source Type: research
Abstract Preeclampsia is defined as new-onset hypertension after the 20th week of gestation along with evidence of maternal organ failure. Rates of preeclampsia have steadily increased over the past 30 years, affecting approximately 4% of pregnancies in the United States and causing a high economic burden. The pathogenesis is multifactorial, with acknowledged contributions by placental, vascular, renal, and immunological dysfunction. Treatment is limited, commonly employing symptomatic management and/or early delivery of the fetus. Along with significant peripartum morbidity and mortality, current research continu...
Source: Am J Physiol Renal P... - Category: Urology & Nephrology Authors: Tags: Am J Physiol Renal Physiol Source Type: research
ia JB Abstract Metformin, an adenosine monophosphate-activated protein kinase (AMPK) activator, has been shown in previous studies to reduce kidney fibrosis in different models of experimental chronic kidney disease (CKD). However, in all of these studies, the administration of metformin was initiated before the establishment of renal disease, which is a condition that does not typically occur in clinical settings. The aim of the present study was to investigate whether the administration of metformin could arrest the progression of established renal disease in a well-recognized model of CKD, the subtotal kidney n...
Source: Am J Physiol Renal P... - Category: Urology & Nephrology Authors: Tags: Am J Physiol Renal Physiol Source Type: research
More News: Chronic Kidney Disease | Pharmaceuticals | Urology & Nephrology | Vitamin K | Vitamins